Spondyloarthritis and quality of life;Spondyloarthritis und lebensqualität

Zeitschrift fur Rheumatologie

Volumn 69, Issue 3, 2010, Pages 213-219

  Hermann, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Ability to function; Disease activity; EQ 5D; Measuring instrument; SF 36

Indexed keywords

ANKYLOSING SPONDYLITIS; DISEASE ACTIVITY; EDUCATION; FUNCTIONAL DISEASE; HUMAN; INFLAMMATION; LANGUAGE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SHORT FORM 12; SHORT FORM 36;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPONDYLITIS, ANKYLOSING;

EID: 77955565853     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0572-x     Document Type: Review

References (28)

1. Schipper H (1996) Quality of life studies: Definitions and conceptual issues. Lippincott-Raven, Philadelphia, pp 11-23
2. The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
3. Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233
4. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483
5. Bullinger M, Kirchberger I (1995) Der deutsche SF-36 Health Survey. Übersetzung und psychometrische Testung eines krankheitsübergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualität. Z Gesundheitswiss 3:21-36
6. Gandek B, Ware JE, Aaronson NK et al (1998) Crossvalidation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International quality of life assessment. J Clin Epidemiol 51:1171-1178
7. Greiner W, Claes C, Busschbach JJ et al (2005) Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 6:124-130
8. Doward LC, Spoorenberg A, Cook SA et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20-26
9. Daltroy LH, Larson MG, Roberts NW et al (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17:946-950
10. Haywood KL, A MG, Jordan K et al (2002) Diseasespecific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41:1295-1302
11. Barkham N, Kong KO, Tennant A et al (2005) The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) 44:1277-1281
12. Dagfinrud H, Mengshoel AM, Hagen KB et al (2004) Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 63:1605-1610
13. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49:483-487
14. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12:247-255
15. Haibel H, Rudwaleit M, Sieper J (2006) Outcome parameters in ankylosing spondylitis. Z Rheumatol 65:131-134, 136-138
16. Lubrano E, D'Angelo S, Parsons WJ et al (2006) Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. J Rheumatol 33:2029-2034
17. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187-1193
18. Brandt J, Khariouzov A, Listing J et al (2003) Sixmonth results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667-1675
19. Davis JC Jr, Revicki D, Heijde DM van der et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57:1050-1057
20. Gladman DD, Mease PJ, Healy P et al (2007) Outcome measures in psoriatic arthritis. J Rheumatol 34:1159-1166
21. Salaffi F, Carotti M, Gasparini S et al (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25
22. Kavanaugh A, Antoni C, Krueger GG et al (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65:471-477
23. Anandarajah AP, Schwarz EM, Totterman S et al (2008) The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 67:296-301
24. Gladman DD, Mease PJ, Cifaldi MA et al (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66:163-168
25. Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976-986
26. Nash P, Thaci D, Behrens F et al (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212:238-249
27. McKenna SP, Doward LC, Whalley D et al (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63:162-169
28. Marzo-Ortega H, McGonagle D, Rhodes LA et al (2007) Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 66:778-781